Circulating endothelial cells: potential prognostic biomarker for sudden heart attack
Although genomics has advanced scientific understanding about the underpinnings of disease, much of that progress has occurred in cancer because tissue-specific molecular characteristics, such as somatic mutations, epigenomics and regulatory elements, can be analyzed in tumor tissue obtained through biopsy or surgical resection.
In patients with coronary artery disease, however, scientists do not have access to the diseased arterial tissue except via the newfound opportunity for isolating and fully characterizing circulating endothelial cells (CECs).
Almost a decade ago, researchers identified significant levels of CECs in the blood of individuals who were at high risk for, or already had, an acute myocardial infarction (MI) or ischemic stroke. Subsequently several additional studies validated CECs as a potential biomarker for vascular injury. However, the cells’ molecular characteristics or ultrastructure have yet to be defined. These mature CECs may harbor key genetic and ultrastructural features that predispose patients to acute vascular injury events.
To better understand the mechanisms leading to acute arterial plaque rupture or erosion in patients with myocardial infarction and stroke, Scripps Translational Science Institute (STSI) researchers are sequencing the DNA of both CECs and germ-line cells. RNA sequencing, mRNA expression profiles and a determination of the ultrastructural characteristics of CECs also are part of the research.
The results may lay the groundwork for a point-of-care assay that could be used in prospective clinical trials to assess the validity of CECs as a prognostic biomarker.
“There is robust evidence that markers such as circulating endothelial cells are present in high-risk individuals in detectable numbers even before an acute vascular event such as a heart attack or stroke occurs,” said Samir Damani, M.D., PharmD., who heads the STSI study. “Therefore, if we can find a way to capture these endothelial cells or nucleic acid signatures of these cells from the whole blood in a rapid and clinically feasible way, we could identify individuals at risk for arterial catastrophes before they occur.”
Dr. Damani is part of a trans-disciplinary team that also includes scientists in the Rare Cell Isolation and Identification Program (RCI) and the National Resource for Automated Molecular Microscopy (NRAMM), both based at The Scripps Research Institute. Like STSI, both RCI and NRAMM are supported by grants from the National Center for Research Resources of the National Institutes of Health. The team also includes researchers at the J. Craig Venter Institute andVeridex of Johnson & Johnson.
The researchers are using CECs provided by 250 heart attack patients at Scripps Green Hospital and four other San Diego area hospitals: Scripps Mercy, Pomerado, Sharp Grossmont and Sharp Memorial. Serving as controls are CECs obtained from healthy volunteers.
In addition to establishing the optimal method for isolating CECs that could be used in clinical care, Dr. Damani and his colleagues have provided the first research evidence that CECs derived from MI patients are morphologically distinct from CECs of healthy controls. With their assay, which is highly specific for CECs, they have validated that these cells are highly diagnostic in acute MI and provided the first research evidence that healthy individuals have persistently low CEC levels over time.
STSI Director Eric J. Topol, M.D., who assembled the transdisciplinary team, hopes that the findings also will generate a multi-scale atlas of mature CECs that can be applied on a population-wide basis to tailor risk and therapy based on each individual’s unique cellular pathobiology.
In addition to providing a molecular fingerprint to identify high risk individuals, CECs may improve scientific understanding about the mechanisms of acute arterial plaque rupture. Thus, CECs, which are shed when a plaque ruptures, may serve as a fluid-phase biopsy, a counterpart to the tumor biopsies that have supplied the tissue essential to cancer genetics research. In future studies, STSI researchers will search for the DNA changes that modulate the variable responses to clopidogrel that characterize the patient population.